Literature DB >> 34787085

The Impact of Diagnostic Status on Quality of Life in Irritable Bowel Syndrome.

Gillian Eleanor Cassar1, George Youssef J2, Simon R Knowles3, Richard Moulding1, David Austin1.   

Abstract

BACKGROUND: The aim of the study was to examine the impact of diagnostic status (i.e., having a clinical diagnosis of irritable bowel syndrome (IBS) or being symptomatic but undiagnosed on quality of life (QoL)). We also examined whether the relationships between QoL and variables such as symptom frequency, pain catastrophizing, visceral sensitivity, and psychological distress are moderated by diagnostic status.
METHODS: The online sample comprised 404 participants (Mage = 33.59, SD = 12.43), of which 98 had been diagnosed with IBS and 306 were symptomatic but undiagnosed.
RESULTS: The findings suggest that even after adjusting for symptom frequency, those diagnosed with IBS experience poorer QoL, relative to those without a diagnosis. Moreover, there was evidence that the relationship between specific QoL domains (namely, sex, food avoidance, and health worry) and psychological variables (namely, pain catastrophizing, and depression) was moderated by diagnostic status.
CONCLUSION: The results indicate that diagnostic status in relation to IBS has psychological implications for QoL outcomes distinct from symptom frequency, age, and gender. This highlights a substantial gap in our current understanding of how a diagnosis of IBS can impact the lives of those suffering from IBS symptomology and calls into question the intended purpose of diagnosis.

Entities:  

Mesh:

Year:  2021        PMID: 34787085      PMCID: PMC9366422          DOI: 10.5152/tjg.2021.20517

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  29 in total

1.  Quantifying Rome symptoms for diagnosis of the irritable bowel syndrome.

Authors:  J Y Chang; A E Almazar; G Richard Locke; J J Larson; E J Atkinson; N J Talley; Y A Saito
Journal:  Neurogastroenterol Motil       Date:  2018-04-27       Impact factor: 3.598

2.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

3.  "It Just Is What It Is": The Positive and Negative Effects of Living With Inflammatory Bowel Disease and Irritable Bowel Syndrome.

Authors:  Olivia Skrastins; Paula C Fletcher
Journal:  Clin Nurse Spec       Date:  2018 Jan/Feb       Impact factor: 1.067

Review 4.  Employing Irritable Bowel Syndrome Patient-Reported Outcomes in the Clinical Trenches.

Authors:  Christopher V Almario; Brennan M R Spiegel
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04       Impact factor: 11.382

5.  Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study.

Authors:  P Boyce; J Gilchrist; N J Talley; D Rose
Journal:  Aust N Z J Psychiatry       Date:  2000-04       Impact factor: 5.744

6.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

7.  The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories.

Authors:  P F Lovibond; S H Lovibond
Journal:  Behav Res Ther       Date:  1995-03

8.  Age, Gender and Women's Health and the Patient.

Authors:  Lesley A Houghton; Margaret Heitkemper; Michael Crowell; Anton Emmanuel; Albena Halpert; James A McRoberts; Brenda Toner
Journal:  Gastroenterology       Date:  2016-02-15       Impact factor: 22.682

9.  Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model.

Authors:  Miranda A L van Tilburg; Olafur S Palsson; William E Whitehead
Journal:  J Psychosom Res       Date:  2013-04-09       Impact factor: 3.006

Review 10.  What Is New in Rome IV.

Authors:  Max J Schmulson; Douglas A Drossman
Journal:  J Neurogastroenterol Motil       Date:  2017-04-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.